These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17017519)

  • 1. The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells.
    Maruyama W; Shamoto-Nagai M; Akao Y; Riederer P; Naoi M
    J Neural Transm Suppl; 2006; (70):125-32. PubMed ID: 17017519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells.
    Shamoto-Nagai M; Maruyama W; Akao Y; Osawa T; Tribl F; Gerlach M; Zucca FA; Zecca L; Riederer P; Naoi M
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1253-65. PubMed ID: 15480837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome.
    Shamoto-Nagai M; Maruyama W; Yi H; Akao Y; Tribl F; Gerlach M; Osawa T; Riederer P; Naoi M
    J Neural Transm (Vienna); 2006 May; 113(5):633-44. PubMed ID: 16362626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione redox status in mitochondria and cytoplasm differentially and sequentially activates apoptosis cascade in dopamine-melanin-treated SH-SY5Y cells.
    Naoi M; Yi H; Maruyama W; Inaba K; Shamoto-Nagai M; Akao Y; Gerlach M; Riederer P
    Neurosci Lett; 2009 Nov; 465(2):118-22. PubMed ID: 19737600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromelanin selectively induces apoptosis in dopaminergic SH-SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component.
    Naoi M; Maruyama W; Yi H; Yamaoka Y; Shamoto-Nagai M; Akao Y; Gerlach M; Tanaka M; Riederer P
    J Neurochem; 2008 Jun; 105(6):2489-500. PubMed ID: 18399961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of neuromelanin on oxidative pathways within the human substantia nigra.
    Double KL; Ben-Shachar D; Youdim MB; Zecca L; Riederer P; Gerlach M
    Neurotoxicol Teratol; 2002; 24(5):621-8. PubMed ID: 12200193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
    J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.
    Gerlach M; Double KL; Ben-Shachar D; Zecca L; Youdim MB; Riederer P
    Neurotox Res; 2003; 5(1-2):35-44. PubMed ID: 12832223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism.
    Liu X; Shibata T; Hisaka S; Osawa T
    Brain Res; 2009 Feb; 1254():18-27. PubMed ID: 19101523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The enigma of neuromelanin in Parkinson's disease substantia nigra.
    Youdim MB; Ben-Shachar D; Riederer P
    J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glia protects neurons against extracellular human neuromelanin.
    Depboylu C; Matusch A; Tribl F; Zoriy M; Michel PP; Riederer P; Gerlach M; Becker S; Oertel WH; Höglinger GU
    Neurodegener Dis; 2007; 4(2-3):218-26. PubMed ID: 17596716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity.
    Shamoto-Nagai M; Maruyama W; Hashizume Y; Yoshida M; Osawa T; Riederer P; Naoi M
    J Neural Transm (Vienna); 2007; 114(12):1559-67. PubMed ID: 17690948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells.
    Li J; Scheller C; Koutsilieri E; Griffiths F; Beart PM; Mercer LD; Halliday G; Kettle E; Rowe D; Riederer P; Gerlach M; Rodriguez M; Double KL
    J Neurochem; 2005 Oct; 95(2):599-608. PubMed ID: 16135091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regulation of dopaminergic neuronal death by endogenous dopamine and proteasome activity].
    Izumi Y; Kume T; Akaike A
    Yakugaku Zasshi; 2011 Jan; 131(1):21-7. PubMed ID: 21212609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New face of neuromelanin.
    Double KL; Halliday GM
    J Neural Transm Suppl; 2006; (70):119-23. PubMed ID: 17017518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifications of the iron-neuromelanin system in Parkinson's disease.
    Fasano M; Bergamasco B; Lopiano L
    J Neurochem; 2006 Feb; 96(4):909-16. PubMed ID: 16417570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
    Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
    J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease.
    Fedorow H; Tribl F; Halliday G; Gerlach M; Riederer P; Double KL
    Prog Neurobiol; 2005 Feb; 75(2):109-24. PubMed ID: 15784302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.